Switch to DOR/ISL (100/0.25 mg) QD from Oral ART: an Open-Label Phase 3 Study in Adults with HIV-1

Conference Reports for NATAP

Conference on Retroviruses
and Opportunistic Infections
San Francisco, CA
March 9-12 2025


Switch to DOR/ISL (100/0.25 mg) QD from Oral ART: an Open-Label Phase 3 Study in Adults with HIV-1

	CROI 2025 SF March 9-12